Catalyst Funds Management Pty LTD Silverback Therapeutics, Inc. Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 2,000 shares of SBTX stock, worth $0. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,000Holding current value
$0% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding SBTX
# of Institutions
162Shares Held
65MCall Options Held
910KPut Options Held
550K-
Deerfield Management Company, L.P. (Series C) New York, NY11.1MShares$00.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...